Protein levels could predict if bowel cancer patients will benefit from Avastin

October 23, 2012

Comparing levels of specific proteins that the drug Avastin targets could identify patients with advanced bowel cancer who will benefit from the treatment, according to research published in Clinical Cancer Research.

, or , has been shown to increase survival from bowel cancer in around ten to 15 per cent of patients, but it has been impossible to predict who will benefit.

Avastin works by targeting and blocking the VEGF-A , two major forms of which are VEGF165 and VEGF165b.

VEGF165 helps cancers to grow new , so they can get food and oxygen from the blood - all cancers need a blood supply to be able to survive and grow. Its sister protein, VEGF165b, has the opposite effect and acts as a brake on this growth.

Cancer Research UK funded scientists at the University of Bristol looked at the effect Avastin had on patients with different levels of VEGF165b and compared this with patients who were not given the drug at all.

Those with low levels of VEGF165b survived three months longer without the disease progressing compared to patients not treated with Avastin. But patients with higher levels of the protein saw no benefit from Avastin and survived no longer than as those who were not given the drug.

Avastin blocks both forms of VEGF-A, so in patients with lower levels of VEGF165b more Avastin may be available to block the blood vessel promoting protein VEGF165, eventually starving the cancer.

Professor David Bates, lead researcher from the University of Bristol's School of Physiology and , said: "Avastin has shown great potential for a minority of people with bowel cancer, but it's been impossible to predict who will benefit from the drug. Currently, Avastin is not approved by NICE for patients with advanced bowel cancer because they feel that the benefit to an unknown minority of patients does not justify the cost of treatment.

"We now need to look at cancer samples from a larger group of patients about to start taking Avastin and determine if the amount of VEGF165b can accurately identify those patients that will benefit and so potentially open a new treatment option for some people with advanced bowel cancer."

is the third most common cancer in the UK with around 41,000 people diagnosed each year. Survival rates have doubled over the last 40 years but 16,000 people still die from the disease.

Dr Julie Sharp, senior science information manager at Cancer Research UK, said: "New targeted treatments can be hugely beneficial for certain patients, depending on the characteristics of their tumour. But, we don't always know who these patients are. This work takes researchers a step closer to developing a suitable test so doctors can give Avastin to those people it will really make a difference to."

Explore further: Avastin no benefit to older lung cancer patients: study

Related Stories

Avastin no benefit to older lung cancer patients: study

April 17, 2012
(HealthDay) -- Medicare patients who have advanced non-small cell lung cancer appear to get no survival benefit from adding the drug Avastin to standard chemotherapy, researchers from the Dana-Farber Cancer Institute report.

Blood proteins may identify vulnerability of pancreatic cancers to avastin

June 7, 2011
(Medical Xpress) -- Tiny tumor proteins circulating in blood may be used to identify which pancreatic cancer patients would benefit from the drug Avastin, researchers at Duke University Medical Center have found.

US revokes Roche's Avastin for breast cancer

November 18, 2011
US health officials on Friday revoked the authorization of Roche's Avastin for breast cancer treatment, saying it concluded the drug had "not been shown to be safe and effective for that use."

Avastin disappoints against ovarian cancer

December 28, 2011
Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too. Two studies found it did not improve survival for most of these patients and kept their ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.